TRIESENBERG, Liechtenstein– Lysando AG – market leader in the field of antimicrobial proteins – has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea.
In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement.
“Amicogen is our first choice for process development and scale-up of any new Artilysin®”, says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. “This important step in our partnership with Amicogen will help our customers to significantly shorten the time-to-market of Artilysin®-powered products.”
Amicogen is an established and professional partner enabling Lysando to develop its own projects to market-readiness at maximum speed, thus further accelerating Lysando’s entry into the pharmaceutical industry. Ongoing projects targeting indications such as urinary tract infections or neurodermatitis are progressing well.
